Effect of the ethanol extract of Syzygium aromaticum (clove) leaves on the lipid profile and body weight in testosterone-induced benign prostatic hyperplasia rats

Abstract

The ethanol extract of Syzygium aromaticum (clove) has attracted attention for its potential effects on lipid metabolism and body weight. The current study investigated the effects of the ethanol extract of Syzygium aromaticum (clove) leaves on the lipid profile and body weight changes in testosterone-induced benign prostatic hyperplasia (BPH) rats. Thirty-six rats were divided into six groups (n = 6/group): normal control, clove extract only (600 mg/kg body weight), testosterone-induced BPH control, finasteride-treated testosterone-induced BPH (3 mg/kg body weight), clove extract-treated testosterone-induced BPH (300 mg/kg body weight), and clove extract-treated testosterone-induced BPH (600 mg/kg body weight). The animals’ body weight was recorded weekly. Treatment lasted for 28 days, after which blood samples were collected for biochemical analysis. Lipid profile analysis showed significant decreases in triacylglycerol, total cholesterol, low-density lipoprotein, and very low-density lipoprotein concentrations in the treatment groups compared with the testosterone-induced BPH control. A significant increase in high-density lipoprotein cholesterol concentration was observed in the treatment groups compared with the testosterone-induced BPH control. Additionally, body weight increased significantly in the treatment groups compared with the testosterone-induced BPH control. These findings suggest that the ethanol extract of clove leaves has anti-hyperlipidemic effects in BPH and may modulate body weight by promoting metabolic activity.

Keywords

Syzygium aromaticum / Lipid profile / Body weight / Testosterone / Benign prostatic hyperplasia / Finasteride

References

[1] AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia. Chapter 1: Diagnosis and treatment recommendations. J Urol. 2003; 170(2):530-547. doi: 10.1097/01.ju.0000078083.38675.79

[2] Asuk AA, Ugwu MN. Nephrotoprotective effect of Vernonia amygdalina (bitter leaf) extract on benign prostatic hyperplasia in adult male rats. Int J Biochem Res Rev. 2018; 22(4):1-9. doi: 10.9734/IJBCRR/2018/42910

[3] Foster HE, Barry MJ, Dahm P, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline. J Urol. 2018; 200(3):612-619. doi: 10.1016/j.juro.2018.05.048

[4] Lekili M, Müezzinoğlu T, Uyanık BS, et al. Serum lipid levels in benign prostatic hyperplasia. World J Urol. 2006; 24(2):210-213. doi: 10.1007/s00345-006-0062-6

[5] Gacci M, Corona G, Vignozzi L, et al. Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. BJU Int. 2014; 115(1):24-31. doi: 10.1111/bju.12728

[6] Lee YJ, Lee JW, Park J, et al. Nationwide incidence and treatment pattern of benign prostatic hyperplasia in Korea. Investig Clin Urol. 2016; 57(6):424. doi: 10.4111/icu.2016.57.6.424

[7] Csikós E, Horváth A, Ács K, et al. Treatment of Benign Prostatic Hyperplasia by Natural Drugs. Molecules. 2021; 26(23):7141. doi: 10.3390/molecules26237141

[8] McConnell JD, Roehrborn CG, Bautista OM, et al. The Long- Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia. N Engl J Med. 2003; 349(25):2387-2398. doi: 10.1056/nejmoa030656

[9] Lee SW, Paick JS, Park HJ, et al. The Efficacy and Safety of Tadalafil 5 mg Once Daily in Korean Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: An Integrated Analysis. World J Mens Health. 2014; 32(1):28. doi: 10.5534/wjmh.2014.32.1.28

[10] Henry G, Malewska A, Mauck R, et al. Molecular pathogenesis of human prostate basal cell hyperplasia. Prostate. 2017; 77(13):1344-1355. doi: 10.1002/pros.23394

[11] Novara G, Galfano A, Gardi M, Ficarra V, Boccon-Gibod L, Artibani W. Critical Review of Guidelines for BPH Diagnosis and Treatment Strategy. Eur Urol Suppl. 2006; 5(4):418-429. doi: 10.1016/j.eursup.2006.02.005

[12] De Souza PAR, Palumbo A Jr, Alves LM, et al. Effects of a nanocomposite containing Orbignya speciosa lipophilic extract on Benign Prostatic Hyperplasia. J Ethnopharmacol. 2011; 135(1):135-146. doi: 10.1016/j.jep.2011.03.003

[13] Chaieb K, Hajlaoui H, Zmantar T, et al. The chemical composition and biological activity of clove essential oil, Eugenia caryophyllata (Syzigium aromaticum L. Myrtaceae): a short review. Phytother Res. 2007; 21(6):501-506. doi: 10.1002/ptr.2124

[14] Nandeesh R, Srinivasa B, Kumar A, et al. Evaluation of hair growth activity of Buxus wallichiana baill extracts in rats. Iran J Basic Med Sci. 2009; 11(4):236-241.

[15] McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA Guideline on the Management of Benign Prostatic Hyperplasia. J Urol. 2011; 185(5):1793-1803. doi: 10.1016/j.juro.2011.01.074

[16] Pinggera GM, Frauscher F. Do we really need herbal medicine in LUTS/BPH treatment in the 21st century? Expert Opin Drug Saf. 2016; 15(12):1573-1575. doi: 10.1080/14740338.2016.1214267

[17] Ejike C, Ezeanyika L. Management of experimental benign prostatic hyperplasia in rats using a food-based therapy containing Telfairia occidentalis seeds. Afr J Tradit Complement Altern Med. 2011; 8(4). doi: 10.4314/ajtcam.v8i4.9

[18] Cai H, Zhang G, Yan Z, Shang X. The Effect of Xialiqi Capsule on Testosterone-Induced Benign Prostatic Hyperplasia in Rats. Evid Based Complement Alternat Med. 2018; 2018:5367814.doi: 10.1155/2018/5367814

[19] Loughlin KR. The testosterone conundrum: The putative relationship between testosterone levels and prostate cancer. Urol Oncol. 2016; 34(11):482.e1-482.e4. doi: 10.1016/j.urolonc.2016.05.023

[20] National Research Council (US) Institute for Laboratory Animal Research. Guide for the Care and Use of Laboratory Animals. Washington, DC, USA: National Academies Press; 1996.

[21] Lorke D. A new approach to practical acute toxicity testing. Arch Toxicol. 1983; 54:275-287. doi: 10.1007/BF01234480

[22] Zlatkis AB, Zak B, Boyle A. A new method for the direct determination of serum cholesterol. J Lab Clin Med. 1953; 4:486-492.

[23] Foster LB, Dunn RT. Stable Reagents for Determination of Serum Triglycerides by a Colorimetric Hantzsch Condensation Method. Clin Chem. 1973; 19(3):338-340. doi: 10.1093/clinchem/19.3.338

[24] Burstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res. 1970; 11(6):583-595. doi: 10.1016/s0022-2275(20)42943-8

[25] Friedewald WT, Levy RI, Fredrickson DS. Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge. Clin Chem. 1972; 18(6):499-502. doi: 10.1093/clinchem/18.6.499

[26] Chiong E, Wong AFW, Chan YH, et al. Review of clinical manifestations of biochemically-advanced prostate cancer cases. Asian J Surg. 2005; 28(3):202-206. doi: 10.1016/S1015-9584(09)60344-4

[27] Sharma M, Chadha R, Dhingra N, et al. Phytotherapeutic agents for benign prostatic hyperplasia: An overview. MRMC. 2017; 17(14):1346-1363. doi: 10.2174/1389557516666160621103817

[28] Farombi EO, Owoeye O. Antioxidative and Chemopreventive Properties of Vernonia amygdalina and Garcinia biflavonoid. Int J Environ Res Public Health. 2011; 8(6):2533-2555. doi: 10.3390/ijerph8062533

[29] Igharo OG, Akinfenwa Y, Isara AR, et al. Lipid profile and atherogenic indices in Nigerians occupationally exposed to e-waste: A cardiovascular risk assessment study. Maedica. 2020; 15(2):196-205. doi: 10.26574/maedica.2020.15.2.196

[30] Onyeabo C, Achi KN, Anyiam PN, et al. Hypolipidemic and Antioxidants Properties of Methanol Leaf Extract of Laportea aestuans on Androgen-Induced Benign Prostatic Hyperplasia in Wistar Rats. Niger J Pharm Res. 2022; 17(2):213-221. doi: 10.4314/njpr.v17i2.7

[31] Parsons JK, Bergstrom J, Barrett-Connor E, et al. Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men. BJU Int. 2008; 101(3):313-318. doi: 10.1111/j.1464-410X.2007.07332.x

[32] Zhang D, Garuti R, Tang W, et al. Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc Natl Acad Sci USA. 2008; 105(35):13045-13050. doi: 10.1073/pnas.0806312105

[33] Akbari F, Azadbakht M, Megha K, et al. Evaluation of Juniperus communis L. seed extract on benign prostatic hyperplasia induced in male Wistar rats. Afr J Urol. 2021; 27:48. doi: 10.1186/s12301-021-00137-x

[34] Mandal D, Sarkar T, Chakraborty R, et al. Critical review on nutritional, bioactive, and medicinal potential of spices and herbs and their application in food fortification and nanotechnology. Appl Biochem Biotechnol. 2023; 195(2):1319-1513. doi: 10.1007/s12010-022-04132-y

[35] Wu X, Gu Y, Li L, et al. The anti-hyperplasia, anti-oxidative and anti-inflammatory properties of Qing Ye Dan and swertiamarin in testosterone-induced benign prostatic hyperplasia in rats. Toxicol Lett. 2017; 265:9-16. doi: 10.1016/j.toxlet.2016.11.011